^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hairy Cell Leukemia |
| Drug: | Rituxan Hycela (rituximab/hyaluronidase) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Hairy Cell Leukemia: Rituximab and hyaluronidase human injection for subcutaneous use is a reasonable alternative for patients who have received at least one full dose of intravenous rituximab.
